S&P 500   3,110.29 (+0.22%)
DOW   27,875.62 (+0.39%)
QQQ   201.83 (+0.06%)
CGC   18.41 (-9.27%)
BABA   186.78 (+1.04%)
GE   11.55 (+0.17%)
T   37.75 (+0.40%)
ACB   2.70 (-13.46%)
F   8.89 (+2.07%)
PRI   130.63 (+0.14%)
NFLX   310.48 (-0.39%)
BAC   33.18 (+1.04%)
DIS   148.29 (+0.95%)
S&P 500   3,110.29 (+0.22%)
DOW   27,875.62 (+0.39%)
QQQ   201.83 (+0.06%)
CGC   18.41 (-9.27%)
BABA   186.78 (+1.04%)
GE   11.55 (+0.17%)
T   37.75 (+0.40%)
ACB   2.70 (-13.46%)
F   8.89 (+2.07%)
PRI   130.63 (+0.14%)
NFLX   310.48 (-0.39%)
BAC   33.18 (+1.04%)
DIS   148.29 (+0.95%)
S&P 500   3,110.29 (+0.22%)
DOW   27,875.62 (+0.39%)
QQQ   201.83 (+0.06%)
CGC   18.41 (-9.27%)
BABA   186.78 (+1.04%)
GE   11.55 (+0.17%)
T   37.75 (+0.40%)
ACB   2.70 (-13.46%)
F   8.89 (+2.07%)
PRI   130.63 (+0.14%)
NFLX   310.48 (-0.39%)
BAC   33.18 (+1.04%)
DIS   148.29 (+0.95%)
S&P 500   3,110.29 (+0.22%)
DOW   27,875.62 (+0.39%)
QQQ   201.83 (+0.06%)
CGC   18.41 (-9.27%)
BABA   186.78 (+1.04%)
GE   11.55 (+0.17%)
T   37.75 (+0.40%)
ACB   2.70 (-13.46%)
F   8.89 (+2.07%)
PRI   130.63 (+0.14%)
NFLX   310.48 (-0.39%)
BAC   33.18 (+1.04%)
DIS   148.29 (+0.95%)
Log in

Corcept Therapeutics Stock Price, Forecast & Analysis (NASDAQ:CORT)

$13.03
+0.06 (+0.46 %)
(As of 11/22/2019 04:00 PM ET)
Today's Range
$12.47
Now: $13.03
$13.14
50-Day Range
$12.88
MA: $14.66
$17.15
52-Week Range
$9.14
Now: $13.03
$19.48
Volume1.43 million shs
Average Volume973,467 shs
Market Capitalization$1.49 billion
P/E Ratio21.72
Dividend YieldN/A
Beta1.35
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Current SymbolNASDAQ:CORT
CUSIP21835210
Phone650-327-3270

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$251.25 million
Cash Flow$0.50 per share
Book Value$2.93 per share

Profitability

Net Income$75.41 million

Miscellaneous

Employees166
Market Cap$1.49 billion
Next Earnings Date2/24/2020 (Estimated)
OptionableOptionable

Receive CORT News and Ratings via Email

Sign-up to receive the latest news and ratings for CORT and its competitors with MarketBeat's FREE daily newsletter.


Corcept Therapeutics (NASDAQ:CORT) Frequently Asked Questions

What is Corcept Therapeutics' stock symbol?

Corcept Therapeutics trades on the NASDAQ under the ticker symbol "CORT."

How were Corcept Therapeutics' earnings last quarter?

Corcept Therapeutics Incorporated (NASDAQ:CORT) announced its earnings results on Thursday, November, 7th. The biotechnology company reported $0.22 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $0.19 by $0.03. The biotechnology company had revenue of $81.51 million for the quarter, compared to the consensus estimate of $77.86 million. Corcept Therapeutics had a net margin of 30.41% and a return on equity of 29.08%. The business's revenue for the quarter was up 26.5% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.22 earnings per share. View Corcept Therapeutics' Earnings History.

When is Corcept Therapeutics' next earnings date?

Corcept Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, February 24th 2020. View Earnings Estimates for Corcept Therapeutics.

What price target have analysts set for CORT?

4 brokers have issued 1-year price targets for Corcept Therapeutics' stock. Their forecasts range from $11.00 to $20.00. On average, they anticipate Corcept Therapeutics' share price to reach $15.75 in the next twelve months. This suggests a possible upside of 20.9% from the stock's current price. View Analyst Price Targets for Corcept Therapeutics.

What is the consensus analysts' recommendation for Corcept Therapeutics?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Corcept Therapeutics in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Corcept Therapeutics.

What are Wall Street analysts saying about Corcept Therapeutics stock?

Here are some recent quotes from research analysts about Corcept Therapeutics stock:
  • 1. According to Zacks Investment Research, "Corcept is making good progress with its Cushing's syndrome drug, Korlym. The company's efforts to expand Korlym’s label are encouraging and should boost the drug’s commercial potential going forward. The company is making attempts to develop its pipeline with its most advanced candidate relacorilant, currently investigated for Cushing's syndrome. The successful development of its other pipeline candidates (CORT125281 and CORT118335) will further boost the company’s portfolio and lead to increased sales in future. However, Corcept’s share price movement shows that the stock has underperformed the industry year to date. Moreover, Corcept is solely dependent on Korlym for growth. A decline in Korlym sales will hinder the company’s growth prospects in the future quarters." (7/31/2019)
  • 2. Cantor Fitzgerald analysts commented, "We have a N rating & a $14 PT for CORT based on our valuation of the Korlym + Rela’ franchise. We believe it’s about Rela’ and our question is when will it successfully complete the P3 in Cushing’s & displace Korlym? This thesis is our primary focus since it announced lower-than-projected Korlym rev for 4Q18 & 2019 guidance that points to limited upside potential (~20% midpoint of $285-315M)." (5/1/2019)

Has Corcept Therapeutics been receiving favorable news coverage?

Media coverage about CORT stock has trended somewhat negative on Friday, according to InfoTrie. InfoTrie rates the sentiment of press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Corcept Therapeutics earned a daily sentiment score of -1.9 on InfoTrie's scale. They also gave media headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View News Stories for Corcept Therapeutics.

Who are some of Corcept Therapeutics' key competitors?

What other stocks do shareholders of Corcept Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Corcept Therapeutics investors own include Micron Technology (MU), CA (CA), BlackRock (BLK), NVIDIA (NVDA), Alibaba Group (BABA), Advanced Micro Devices (AMD), Celgene (CELG), AbbVie (ABBV), Endologix (ELGX) and Netflix (NFLX).

Who are Corcept Therapeutics' key executives?

Corcept Therapeutics' management team includes the folowing people:
  • Dr. Joseph K. Belanoff, Co-Founder, Pres, CEO & Director (Age 62)
  • Mr. Gary Charles Robb, CFO & Sec. (Age 56)
  • Mr. Sean Maduck, Sr. VP of Commercial (Age 42)
  • Dr. Christopher Shayne James M.D., Director of Investor Relations
  • Dr. Hazel Hunt Ph.D., Sr. VP of Research

Who are Corcept Therapeutics' major shareholders?

Corcept Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Ingalls & Snyder LLC (7.66%), Parallel Advisors LLC (1.12%), AMI Asset Management Corp (0.68%), Peregrine Capital Management LLC (0.34%), State of New Jersey Common Pension Fund D (0.19%) and California Public Employees Retirement System (0.18%). Company insiders that own Corcept Therapeutics stock include G Leonard Baker Jr, Gary Charles Robb, Joseph K Belanoff, Renee D Gala, Robert S Fishman and Sean Maduck. View Institutional Ownership Trends for Corcept Therapeutics.

Which institutional investors are selling Corcept Therapeutics stock?

CORT stock was sold by a variety of institutional investors in the last quarter, including AMI Asset Management Corp, Russell Investments Group Ltd., Peregrine Capital Management LLC, Trustcore Financial Services LLC, Dupont Capital Management Corp, Virginia Retirement Systems ET AL, Hancock Whitney Corp and Alps Advisors Inc.. Company insiders that have sold Corcept Therapeutics company stock in the last year include G Leonard Baker Jr, Gary Charles Robb, Joseph K Belanoff and Sean Maduck. View Insider Buying and Selling for Corcept Therapeutics.

Which institutional investors are buying Corcept Therapeutics stock?

CORT stock was acquired by a variety of institutional investors in the last quarter, including Parallel Advisors LLC, State of New Jersey Common Pension Fund D, Ingalls & Snyder LLC, California Public Employees Retirement System, Alberta Investment Management Corp, Hussman Strategic Advisors Inc., Chicago Equity Partners LLC and State of Alaska Department of Revenue. Company insiders that have bought Corcept Therapeutics stock in the last two years include G Leonard Baker Jr and Renee D Gala. View Insider Buying and Selling for Corcept Therapeutics.

How do I buy shares of Corcept Therapeutics?

Shares of CORT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Corcept Therapeutics' stock price today?

One share of CORT stock can currently be purchased for approximately $13.03.

How big of a company is Corcept Therapeutics?

Corcept Therapeutics has a market capitalization of $1.49 billion and generates $251.25 million in revenue each year. The biotechnology company earns $75.41 million in net income (profit) each year or $0.60 on an earnings per share basis. Corcept Therapeutics employs 166 workers across the globe.View Additional Information About Corcept Therapeutics.

What is Corcept Therapeutics' official website?

The official website for Corcept Therapeutics is http://www.corcept.com/.

How can I contact Corcept Therapeutics?

Corcept Therapeutics' mailing address is 149 COMMONWEALTH DRIVE, MENLO PARK CA, 94025. The biotechnology company can be reached via phone at 650-327-3270 or via email at [email protected]


MarketBeat Community Rating for Corcept Therapeutics (NASDAQ CORT)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  432 (Vote Outperform)
Underperform Votes:  354 (Vote Underperform)
Total Votes:  786
MarketBeat's community ratings are surveys of what our community members think about Corcept Therapeutics and other stocks. Vote "Outperform" if you believe CORT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CORT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/22/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel